Today: 9 June 2026
Rolls-Royce share price jumps in early London trade as buyback ticks on, results loom
13 February 2026
2 mins read

Rolls-Royce share price jumps in early London trade as buyback ticks on, results loom

London, Feb 13, 2026, 08:53 GMT — Regular session

  • Shares of Rolls-Royce climbed roughly 3% early Friday in London trading.
  • The latest buyback disclosure revealed the company was still snapping up its own shares through UBS on Feb. 11.
  • With full-year results set for Feb. 26, traders are already making their moves.

Rolls-Royce Holdings (RR.L) bounced 3.2% higher to 1,265.45 pence early Friday in London, recouping losses from the previous day’s drop.

That latest purchase comes as Rolls-Royce keeps working through its interim buyback, giving the shares a consistent floor as earnings season approaches. According to a Thursday daily filing, the company acquired 367,558 shares on the London Stock Exchange on Feb. 11, picking up more stock across other platforms too. Prices ranged from 1,237 pence up to 1,262.5 pence per share. Full details here:

Why it matters now: The buyback is bumping up against the company’s full-year results later this month. Once again, the stock is back in the high-beta spotlight. Bank of America, in a pre-results note highlighted by Interactive Investor this week, pointed to a 1,600 pence target and suggested those annual numbers could spark a move.

Shares in Rolls-Royce have jumped roughly 97% over the past year, according to Hargreaves Lansdown. With the stock now sporting a lofty multiple compared to most of the FTSE 100, there’s little forgiveness for disappointing results. The buyback news has taken on outsized importance as a result.

Rolls-Royce said UBS will handle the share purchases and cancel the stock, after the interim buyback plan was unveiled in December. The company expects the programme to wrap up by Feb. 24.

Here’s how a buyback works: a company spends cash to buy back its own shares, cutting the share count and, assuming everything else stays the same, pushing up earnings per share. This move also tells investors management feels confident enough about its finances to hand back cash rather than hold it for operations.

The broader market held steady in early trading. The FTSE 100 nudged up 0.2%, with Rolls-Royce standing out as one of the session’s top-performing blue chips.

But there’s no sure thing here. Tougher supply-chain snags could bite, or shop visits and engine time-on-wing might not live up to hopes—either way, the cash supporting the buyback could get shaky.

Rolls-Royce shares shed 1.8% by the close Thursday, ending at 1,226 pence after a turbulent session that saw the stock shift between 1,223 and 1,269 pence, according to MarketWatch data.

Rolls-Royce is pumping out repurchase updates almost every day. In its latest filing Wednesday, the company disclosed it scooped up 359,358 shares on the LSE on Feb. 10, with additional buying on other platforms; those shares, too, are slated for cancellation.

One date investors are circling: Feb. 26. That’s when Rolls-Royce, in its November trading update, said full-year results would land. The company also flagged “continued supply chain challenges” in the same announcement. https://www.rolls-royce.com/~/media/Files/…

Next, attention shifts to buyback disclosure updates as the programme nears its Feb. 24 expected finish. Full-year results follow on Feb. 26.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Anglo American share price in focus before London open as De Beers sale, results loom
Previous Story

Anglo American share price in focus before London open as De Beers sale, results loom

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 14.02.2026

Go toTop